Research
A Phase 3 Trial of L-Glutamine in Sickle Cell Disease
This pivotal, randomized controlled trial demonstrated that oral therapy with pharmaceutical-grade L-Glutamine significantly reduces the frequency of pain crises and hospitalizations in patients with sickle cell disease. The study highlights L-Glutamine's role in mitigating oxidative stress on red blood cells, providing a strong scientific basis for its use in supporting cellular health and function.
A Phase 3 Trial of L-Glutamine in Sickle Cell Disease
This pivotal, randomized controlled trial demonstrated that oral therapy with pharmaceutical-grade L-Glutamine significantly reduces the frequency of pain crises and hospitalizations in patients with sickle cell disease. The study highlights L-Glutamine's role in mitigating oxidative stress on red blood cells, providing a strong scientific basis for its use in supporting cellular health and function.